Trials / Recruiting
RecruitingNCT06807619
A Study of Sotorasib in People With Brain Tumors
BrainMet ADePPT (Anticancer Drug Penetration Platform Trial)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out how effective sotorasib is at getting into KRAS G12C+ brain tumors. The researchers will also find out whether sotorasib is a safe and effective treatment for people undergoing surgical resection of KRAS G12C+ metastatic brain tumors, and do tests that show how the body absorbs, distributes, and gets rid of sotorasib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sotorasib | Enrolled patients will be administered DCOI at the FDA-recommended dose or continued on the DCOI at the discretion of the treating Oncologist per standard of care |
Timeline
- Start date
- 2025-01-29
- Primary completion
- 2028-01-01
- Completion
- 2028-01-01
- First posted
- 2025-02-04
- Last updated
- 2025-05-22
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06807619. Inclusion in this directory is not an endorsement.